Skip to main content

Multiple Sclerosis Topic Center

Industry Insights

conference coverage


Conference Coverage
06/03/2025
Juliet Gallagher
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become...
06/03/2025
First Report Managed Care
Conference Coverage
06/02/2025
Juliet Gallagher
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers...
06/02/2025
First Report Managed Care
Conference Coverage
05/29/2025
Grace Taylor, MS, MA
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that...
05/29/2025
First Report Managed Care
Conference Coverage
05/28/2025
Hannah Musick
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease...
05/28/2025
First Report Managed Care
Conference Coverage
05/28/2025
Juliet Gallagher
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC...
05/28/2025
First Report Managed Care
Conference Coverage
03/13/2025
Juliet Gallagher
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
03/04/2025
Hannah Musick
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
03/04/2025
Hannah Musick
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
02/27/2025
Grace Taylor, MS, MA
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
02/27/2025
Grace Taylor, MS, MA
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care